Frank Yocca

Company: BioXcel
Job title: Senior Vice President & Chief Scientific Officer
Seminars:
IGALMI: Sublingual Dexmedetomidine for the Acute Treatment of Agitation in Schizophrenia and Bipolar Disorder 11:45 am
Use of AI for identifying and developing a therapeutic for an underserved indication Overview and key decisions/data in the discovery, formulation and development of IGALMI for treating acute agitation Applying a “Land and Expand” strategy for new indications and broadening commercial opportunities for IGALMIRead more
day: Day One